Evidence map›Paper›PMID 33453143›Full record

ReviewAngewandte Chemie (International ed. in English)2021

Enzymatic Late-Stage Modifications: Better Late Than Never.

Elvira Romero, Bethan S Jones, Bethany N Hogg, Arnau Rué Casamajo, Martin A Hayes, Sabine L Flitsch, Nicholas J Turner, Christian Schnepel

Abstract readReview
In one paragraph

Review in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Article
  2. Next-Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca.Chembiochem : a European journal of chemical biology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. An Update: Enzymatic Synthesis for Industrial Applications.Angewandte Chemie (International ed. in English) · 2025
    Review
  12. Article
  13. Biocatalytic diversification of abietic acid in Streptomyces.Journal of industrial microbiology & biotechnology · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elvira RomeroCompound Synthesis and Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-4199-9458
Bethan S JonesSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0002-3813-7876
Bethany N HoggSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0002-9432-9936
Arnau Rué CasamajoSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0001-8932-8763
Martin A HayesCompound Synthesis and Management, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-2640-8464
Sabine L FlitschSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0003-3974-646X
Nicholas J TurnerSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0002-8708-0781
Christian SchnepelSchool of Chemistry, The University of Manchester, Manchester Institute of Biotechnology, 131 Princess Street, Manchester, M1 7DN, United Kingdom.ORCID 0000-0002-4331-2675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzyme catalysis is gaining increasing importance in synthetic chemistry. Nowadays, the growing number of biocatalysts accessible by means of bioinformatics and enzyme engineering opens up an immense variety of selective reactions. Biocatalysis especially provides excellent opportunities for late-stage modification often superior to conventional de novo synthesis. Enzymes have proven to be useful for direct introduction of functional groups into complex scaffolds, as well as for rapid diversification of compound libraries. Particularly important and highly topical are enzyme-catalysed oxyfunctionalisations, halogenations, methylations, reductions, and amide bond formations due to the high prevalence of these motifs in pharmaceuticals. This Review gives an overview of the strengths and limitations of enzymatic late-stage modifications using native and engineered enzymes in synthesis while focusing on important examples in drug development.

Indexed as

AmidesBiocatalysisEnzymesAmidesEnzymesdiversificationenzyme engineeringlate-stage functionalisationoxyfunctionalisationselectivity

Identifiers

PMID33453143
PMCPMC8359417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.